| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S1286-4579(01)01524-6 |
| P698 | PubMed publication ID | 11880048 |
| P2093 | author name string | John E Hyde | |
| P2860 | cites work | Artemisinin, an Endoperoxide Antimalarial, Disrupts the Hemoglobin Catabolism and Heme Detoxification Systems in Malarial Parasite | Q22061847 |
| A mechanism for the synergistic antimalarial action of atovaquone and proguanil | Q24550657 | ||
| Assessment of the pharmacodynamic properties of antimalarial drugs in vivo | Q24670346 | ||
| Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action | Q27627235 | ||
| Structure and function of the dihydropteroate synthase from Staphylococcus aureus | Q27737332 | ||
| Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase | Q27739215 | ||
| Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum | Q27861931 | ||
| Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria | Q27861937 | ||
| Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum | Q27861947 | ||
| Characterization of the pfmdr2 gene for Plasmodium falciparum | Q27974630 | ||
| Plasmodium falciparum: the pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite | Q27974631 | ||
| A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum | Q28137798 | ||
| The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin | Q28274190 | ||
| Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites | Q28370808 | ||
| Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance | Q29615118 | ||
| A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole | Q30039339 | ||
| Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum | Q31389858 | ||
| A molecular marker for chloroquine-resistant falciparum malaria | Q31921233 | ||
| Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum | Q33680054 | ||
| An integrated model of chloroquine action | Q33719332 | ||
| Reaction of antimalarial endoperoxides with specific parasite proteins | Q33757165 | ||
| Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria | Q33889085 | ||
| Possible modes of action of the artemisinin-type compounds. | Q34207723 | ||
| Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene | Q34370204 | ||
| Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea | Q46340740 | ||
| Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair | Q46617407 | ||
| Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance | Q46878245 | ||
| Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action | Q47308607 | ||
| Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. | Q47829427 | ||
| Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast | Q47836741 | ||
| Towards an understanding of drug resistance in malaria: three-dimensional structure of Plasmodium falciparum dihydrofolate reductase by homology building | Q47850639 | ||
| Cross-resistance between mefloquine and halofantrine | Q47873193 | ||
| Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens | Q47874225 | ||
| The interaction of artemisinin with malarial hemozoin | Q48016192 | ||
| Atovaquone and proguanil for Plasmodium falciparum malaria | Q48028627 | ||
| Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro | Q48033106 | ||
| A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance | Q48037412 | ||
| Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid | Q69887088 | ||
| Synergistic Antimalarial Activity of Pyrimethamine and Sulfadoxine against Plasmodium falciparum In Vitro * | Q70360226 | ||
| Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase | Q73475729 | ||
| Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum | Q35618862 | ||
| Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase | Q35988728 | ||
| Variations in frequencies of drug resistance in Plasmodium falciparum | Q36567189 | ||
| Susceptibility of Plasmodium falciparum to five drugs: an in vitro study of isolates mainly from Thailand | Q36600007 | ||
| The dynamics of drug resistance in Plasmodium falciparum | Q37298103 | ||
| Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. | Q37485888 | ||
| Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine | Q37559063 | ||
| Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine | Q37731639 | ||
| The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites | Q38022617 | ||
| Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine | Q38345011 | ||
| Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa | Q38895529 | ||
| Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum. | Q38920326 | ||
| Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum | Q38980049 | ||
| Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand | Q39188543 | ||
| Drug resistance in malaria parasites of animals and man. | Q39351674 | ||
| Short report: gametocytes, chloroquine pressure, and the relative parasite survival advantage of resistant strains of falciparum malaria in west Africa | Q39401513 | ||
| Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site | Q39474607 | ||
| Epidemiology of drug resistance in malaria | Q39587600 | ||
| Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand | Q39596627 | ||
| Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. | Q39596634 | ||
| In vitro activities of and mechanisms of resistance to antifol antimalarial drugs | Q39849631 | ||
| Mitochondrial protein import: mechanisms, components and energetics | Q40696648 | ||
| Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum | Q41819350 | ||
| Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. | Q41913045 | ||
| Reversal of chloroquine resistance in Plasmodium falciparum by verapamil | Q41914126 | ||
| Studies of resistance to chloroquine, quinine, amodiaquine and mefloquine among Philippine strains of Plasmodium falciparum | Q41917819 | ||
| Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. | Q41919748 | ||
| Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum | Q41921101 | ||
| Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy | Q41923816 | ||
| A common mechanism for blockade of heme polymerization by antimalarial quinolines | Q41925197 | ||
| Access to hematin: the basis of chloroquine resistance. | Q41926063 | ||
| Plasmodium falciparum: in vitro chloroquine susceptibility and allele-specific PCR detection of Pfmdr1 Asn86Tyr polymorphism in Lambarene, Gabon | Q41926777 | ||
| Pfmdr1 Asn1042Asp and Asp1246Tyr polymorphisms, thought to be associated with chloroquine resistance, are present in chloroquine-resistant and -sensitive Brazilian field isolates of Plasmodium falciparum | Q41927026 | ||
| Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa | Q41927511 | ||
| Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins | Q41927581 | ||
| Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum | Q41928961 | ||
| Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization | Q41928982 | ||
| Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite | Q41929069 | ||
| In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1. | Q41929662 | ||
| The ATP-binding cassette (ABC) gene family of Plasmodium falciparum. | Q41931004 | ||
| Plasmodium falciparum: molecular characterization of multidrug-resistant Cambodian isolates | Q41931399 | ||
| Effects of antimalarials and protease inhibitors on plasmodial hemozoin production | Q41934587 | ||
| Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. | Q41934737 | ||
| Plasmodium falciparum in Owl Monkeys: Drug Resistance and Chloroquine Binding Capacity | Q41937824 | ||
| Kinetic modelling of chloroquine uptake by malaria-infected erythrocytes. Assessment of the factors that may determine drug resistance | Q41942038 | ||
| Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum | Q41943905 | ||
| Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross | Q41943911 | ||
| Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum | Q41945692 | ||
| Sulfa-drug resistance in Plasmodium falciparum | Q43653651 | ||
| Plasmodium falciparum: gene mutations and amplification of dihydrofolate reductase genes in parasites grown in vitro in presence of pyrimethamine. | Q43683365 | ||
| An RFLP map of the Plasmodium falciparum genome, recombination rates and favored linkage groups in a genetic cross | Q44141553 | ||
| Molecular assays for surveillance of antifolate-resistant malaria | Q45141285 | ||
| Selection and synergy in Plasmodium falciparum | Q46192435 | ||
| P433 | issue | 2 | |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| antimalarial | Q521616 | ||
| P304 | page(s) | 165-174 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Microbes and Infection | Q15760242 |
| P1476 | title | Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs | |
| P478 | volume | 4 |
| Q53696597 | Altered life history strategies protect malaria parasites against drugs. |
| Q35991786 | Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii |
| Q34246952 | Anti-plasmodial activities and X-ray crystal structures of rotenoids from Millettia usaramensis subspecies usaramensis |
| Q37820670 | Antimalarial drugs: modes of action and mechanisms of parasite resistance |
| Q40588066 | Antimalarial potential of leaves of Chenopodium ambrosioides L. |
| Q42112205 | Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening |
| Q39565472 | Assessment of SYBR green I dye-based fluorescence assay for screening antimalarial activity of cationic peptides and DNA intercalating agents |
| Q41900287 | Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay |
| Q37340296 | Catalytic and ligand-binding characteristics of Plasmodium falciparum serine hydroxymethyltransferase |
| Q21032482 | Challenges of drug-resistant malaria |
| Q42721596 | Characterisation of exogenous folate transport in Plasmodium falciparum |
| Q38357113 | Characterization of a unique aspartate-rich protein of the SET/TAF-family in the human malaria parasite, Plasmodium falciparum, which inhibits protein phosphatase 2A. |
| Q27657068 | Crystallographic structure of the tetratricopeptide repeat domain ofPlasmodium falciparumFKBP35 and its molecular interaction with Hsp90 C-terminal pentapeptide |
| Q35056015 | Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development |
| Q93060304 | Deployment and utilization of next-generation sequencing of Plasmodium falciparum to guide anti-malarial drug policy decisions in sub-Saharan Africa: opportunities and challenges |
| Q36295369 | Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum |
| Q37265469 | Disruption of a mitochondrial MutS DNA repair enzyme homologue confers drug resistance in the parasite Toxoplasma gondii |
| Q36248426 | Drug-resistant malaria |
| Q36933785 | Drug-resistant malaria - an insight |
| Q33739065 | Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study |
| Q35127944 | Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays. |
| Q36104143 | Exploring the folate pathway in Plasmodium falciparum |
| Q37126331 | Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger |
| Q27641127 | Glutathione reductase of the malarial parasite Plasmodium falciparum: crystal structure and inhibitor development |
| Q37731378 | Herbicidal properties of antimalarial drugs |
| Q28829342 | High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria |
| Q41916347 | Lansium domesticum: skin and leaf extracts of this fruit tree interrupt the lifecycle of Plasmodium falciparum, and are active towards a chloroquine-resistant strain of the parasite (T9) in vitro |
| Q39122575 | Malaria treatment using novel nano-based drug delivery systems |
| Q34407247 | Malaria: an evaluation of the current state of research on pathogenesis and antimalarial drugs. |
| Q34521004 | Medical need, scientific opportunity and the drive for antimalarial drugs |
| Q34960279 | Microbial and viral drug resistance mechanisms |
| Q33309679 | Modeling the inhibition of quadruple mutant Plasmodium falciparum dihydrofolate reductase by pyrimethamine derivatives |
| Q56787190 | Modulation ofAnopheles gambiaeEpsilon glutathione transferase activity by plant natural productsin vitro |
| Q27662615 | NMR and crystallographic structures of the FK506 binding domain of human malarial parasite Plasmodium vivax FKBP35 |
| Q31143848 | Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system |
| Q35026098 | Novel anti-plasmodial hits identified by virtual screening of the ZINC database |
| Q33892979 | Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. |
| Q35875731 | Proteases in host cell invasion by the malaria parasite |
| Q34191903 | Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax |
| Q41943140 | Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro |
| Q39607489 | Selection and reversal of Plasmodium berghei resistance in the mouse model following repeated high doses of artemether |
| Q44416628 | Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-trisubstituted dihydroisoquinolines and isoquinolines |
| Q47825856 | Sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Côte d'Ivoire. |
| Q80786617 | Synthesis and antimalarial evaluation of cyclic beta-amino acid-containing dipeptides |
| Q56380008 | Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of Dihydroorotate Dehydrogenase |
| Q34585708 | Targeting of toxic compounds to the trypanosome's interior |
| Q33467083 | The effect of mimicking febrile temperature and drug stress on malarial development |
| Q24802251 | The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin |
| Q34424514 | The phenothiazinium chromophore and the evolution of antimalarial drugs |
| Q27014881 | Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria |
Search more.